The Mitochondrial K\textsubscript{ATP} Channel as a Receptor for Potassium Channel Openers*

(Received for publication, September 22, 1995, and in revised form, January 15, 1996)

Keith D. Garlid, Petr Paucek, Vladimir Yarov-Yarovoy, Xiaocheng Sun, and Peter A. Schindler†

From the Department of Chemistry, Biochemistry, and Molecular Biology, Oregon Graduate Institute of Science and Technology, Portland, Oregon 97291-1000

The biochemical properties of the mitochondrial K\textsubscript{ATP} channel are very similar to those of plasma membrane K\textsubscript{ATP} channels, including inhibition by low concentrations of ATP and glyburide (Paucek, P., Mironova, G., Mahdi, F., Beavis, A. D., Woldegorgis, G., and Garlid, K. D. (1992) J. Biol. Chem. 267, 26062-26069). Plasma membrane K\textsubscript{ATP} channels are highly sensitive to the family of drugs known as K\textsuperscript+ channel openers, raising the question whether mitochondrial K\textsubscript{ATP} channels are similarly sensitive to these agents. We addressed this question by measuring K\textsuperscript+ flux in intact rat liver mitochondria and in liposomes containing K\textsubscript{ATP} channel purified from rat liver and beef heart mitochondria. K\textsuperscript+ channel openers completely reversed ATP inhibition of K\textsuperscript+ flux in both systems. In liposomes, ATP-inhibited K\textsuperscript+ flux was restored by diazoxide (K\textsubscript{1/2} = 0.4 \mu M), cromakalim (K\textsubscript{1/2} = 1 \mu M), and two developmental cromakalim analogues, EM-D60480 and EM-D57970 (K\textsubscript{1/2} = 6 \mu M). Similar K\textsubscript{1/2} values were observed in intact mitochondria. These potencies were well within the range observed with plasma membrane K\textsubscript{ATP} channels. We also compared the potencies of these K\textsuperscript+ channel openers on the plasma membrane K\textsubscript{ATP} channel purified from beef heart myocytes. The K\textsubscript{ATP} channel from cardiac mitochondria is 2000-fold more sensitive to diazoxide than the channel from cardiac sarcolemma, indicating that two distinct receptor subtypes coexist within the myocyte. We suggest that the mitochondrial K\textsubscript{ATP} channel is an important intracellular receptor that should be taken into account in considering the pharmacology of K\textsuperscript+ channel openers.

K\textsuperscript+ channel openers (KCOs) activate ATP-inhibited K\textsubscript{ATP} channels. As described in several excellent reviews (1-3), members of this drug family exhibit a rich and clinically important pharmacology. Thus, cell membrane K\textsubscript{ATP} channels (cellK\textsubscript{ATP}) in different tissues are considered to mediate the hypotensive and diabetogenic effects of diazoxide (4) and the cardioprotective effects of cromakalim and its derivatives (5). It is important to determine whether these drugs also act on mitochondrial K\textsubscript{ATP} channels (mitoK\textsubscript{ATP}) in their therapeutic range. 3 In the first report of KCO actions in mitochondria, Belyaeva et al. (6) and Szewczyk et al. (7) observed stimulation of K\textsuperscript+ uptake by KCOs in respiring mitochondria. RP66471 was the most potent KCO studied (K\textsubscript{1/2} = 50 \mu M), whereas P1060 and diazoxide were only weakly active at 700 \mu M. Because these concentrations are much higher than K\textsubscript{1/2} values observed with cellK\textsubscript{ATP} (1), these results appear to imply that mitochondrial actions of KCOs are not pharmacologically important. We now report that diazoxide, cromakalim, and two experimental benzopyran derivatives are very potent activators of K\textsuperscript+ flux through ATP-inhibited mitoK\textsubscript{ATP}, with K\textsubscript{1/2} values similar to those observed with cellK\textsubscript{ATP}. KCO activation of K\textsuperscript+ flux was observed in both intact mitochondria and proteoliposomes containing reconstituted mitoK\textsubscript{ATP}. No effect was observed on uninhibited K\textsuperscript+ flux, which likely explains the low potencies observed by previous workers (6, 7) in assays that did not include Mg\textsuperscript{2+} and ATP. We also found that mitoK\textsubscript{ATP} and cellK\textsubscript{ATP} from beef heart differed strongly in their sensitivity to diazoxide, indicating distinct receptor subtypes among K\textsubscript{ATP} channels from the same cell. Our results indicate that mitoK\textsubscript{ATP} may be an important intracellular receptor for K\textsuperscript+ channel openers, and they raise the possibility that mitoK\textsubscript{ATP} is the site of action of cardioprotective KCOs.2

EXPERIMENTAL PROCEDURES

Assays of K\textsuperscript+ Flux in Proteoliposomes Containing Reconstituted MitoK\textsubscript{ATP} Isolated from Rat Liver Mitochondria—MitoK\textsubscript{ATP} was purified and reconstituted into proteoliposomes exactly as described previously (8, 9). Internal medium contained 300 \mu M PBFI, 0.14 mM KC\textsubscript{1}, 1 mM TEA-EDTA, 25 mM TEA-HEPES, and 100 mM TEA-SO\textsubscript{4} (pH 6.8). Vesicles were added in a final concentration of 0.38 mg lipids/ml to external medium containing 150 mM KC\textsubscript{1} and 25 mM TEA-HEPES (pH 7.4) at 25°C. As indicated in the text, external medium also contained 3 mM MgCl\textsubscript{2} or 1 mM TEA-EDTA, and 0.5 mM ATP or no ATP. Electrophoretic K\textsuperscript+ flux was initiated by 1 \mu M carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, which catalyzes charge compensation. K\textsuperscript+ flux was determined by linear regression of the initial changes in the K\textsuperscript+-dependent fluorescence of intraliposomal PBFI, which was calibrated for each preparation (8, 9).

Assays of K\textsuperscript+ Flux in Proteoliposomes Containing Reconstituted CellK\textsubscript{ATP} Isolated from Beef Heart Sarcolemmal Vesicles—Sarcolemmal vesicles were prepared from the left ventricular muscle of fresh beef heart according to a modification (10) of the method of j ones and Besch (11). The sarcolemmal K\textsubscript{ATP} channel was solubilized, purified, and

---

*This research was supported in part by National Institutes of Health Grants GM31086 and HL36573 (to K. D. G.) and a Postdoctoral Fellowship (to P. P.) from the Oregon Affiliate of the American Heart Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

†To whom correspondence and reprint requests should be addressed: Dept. of Chemistry, Biochemistry, and Molecular Biology, Oregon Graduate Institute of Science and Technology, P. O. Box 91000, Portland, OR 97291-1000. Tel.: 503-690-1680; Fax: 503-690-1464; E-mail: garlid-admin@ogi.edu.

‡In partial fulfillment of requirements for the Ph.D. degree.

§Visiting Predoctoral Fellow supported by a Predoctoral Fellowship from Preclinical Cardiovascular Research, E. Merck, Darmstadt, Germany.

1 The abbreviations used are: KCO, potassium channel opener; cellK\textsubscript{ATP}, plasma membrane K\textsubscript{ATP} channel; mitoK\textsubscript{ATP}, mitochondrial K\textsubscript{ATP} channel; PBFI, potassium-binding benzofuran isophthalate; TEA\textsuperscript{−}, tetraethylammonium cation; TES, N-tris(hydroxymethyl)methylaminoethanesulfonic acid; TMPO, N,N,N′,N′-tetramethyl-p-phenylene-diamine.

2 A preliminary report of these findings has been published in abstract form (32).
Pharmacology of the Mitochondrial K\textsubscript{ATP} Channel

RESULTS

Activation of K\textsuperscript{+} Flux through Reconstituted MitoK\textsubscript{ATP} by K\textsuperscript{+} Channel Openers—Fig. 1 contains dose-response curves for KCO stimulation of K\textsuperscript{+} flux in vesicles reconstituted with mitoK\textsubscript{ATP}. Drug assays were carried out in medium containing 3 mM Mg\textsuperscript{2+} and 0.5 mM ATP, which fully inhibits mitoK\textsubscript{ATP} (K\textsubscript{50} (ATP) \approx 22 \mu M). The drugs tested were potent activators of K\textsuperscript{+} flux, restoring ATP-inhibited flux to, but not beyond, control rates measured in the absence of ATP.

Observed K\textsubscript{50} values (mean and S.D.) were 1.05 \pm 0.06 \mu M for cromakalim (n = 5), 0.37 \pm 0.03 \mu M for diazoxide (n = 4), 6.1 \pm 1.3 \mu M for EMD60480 (n = 2), and 6.20 \pm 0.02 \mu M for EMD57970 (n = 2). As shown in the inset to Fig. 1, cromakalim and diazoxide exhibited indistinguishable Hill slopes of 2.0 \pm 0.5, and the benzopyran derivatives yielded Hill slopes of 3.5 \pm 0.3. Hill slopes greater than 1.0 may reflect a tetrameric structure of the channel, as observed with other K\textsuperscript{+} channels (16), or the existence of multiple binding sites on a regulatory ATP binding cassette, as has been proposed for the sulfonylurea receptor of the pancreatic \( \beta \) cell (17).

We also measured KCO activation of K\textsuperscript{+} flux in proteoliposomes reconstituted with mitoK\textsubscript{ATP} purified from beef heart mitochondria. Observed K\textsubscript{50} values from two experiments were 1 \mu M for cromakalim and 0.4 \mu M for diazoxide. These results extend a previous observation that cardiac and hepatic mitoK\textsubscript{ATP} behave very similarly.

We stress that these drugs stimulated K\textsuperscript{+} flux only when K\textsuperscript{+} flux was inhibited by Mg\textsuperscript{2+} and ATP. Control (uninhibited) K\textsuperscript{+} flux is observed in media containing Mg\textsuperscript{2+} alone, ATP alone, and lacking both Mg\textsuperscript{2+} and ATP (8). In each of these conditions, KCOs had no effect on control K\textsuperscript{+} flux at doses up to 30-fold higher than their respective K\textsubscript{50} values.

Activation of K\textsuperscript{+} Flux through Reconstituted Cardiac Plasma Membrane K\textsubscript{ATP} by K\textsuperscript{+} Channel Openers—The high potency of diazoxide for cardiac mitoK\textsubscript{ATP} was somewhat surprising and suggested a pharmacological distinction from cardiac celiK\textsubscript{ATP}, which is relatively insensitive to diazoxide (18). Accordingly, we evaluated the effects of the same set of KCOs on cellK\textsubscript{ATP} reconstituted from cardiac sarcosomal vesicles (12, 19). Fig. 2 contains dose-response curves for KCO stimulation of K\textsuperscript{+} flux in proteoliposomes reconstituted with cardiac cellK\textsubscript{ATP}. These assays were carried out in media containing 2 mM ATP (K\textsubscript{50} = 0.5 \mu M). Each of the drugs restored ATP-inhibited K\textsuperscript{+} flux to control rates measured in the absence of ATP. As was the case with mitoK\textsubscript{ATP}, these KCOs had no effect on the control rate in the absence of ATP. Observed K\textsubscript{50} values and Hill slopes (in parentheses) for opening the plasma membrane K\textsubscript{ATP} channel were 3.7 \mu M (1.1) for EMD57970, 22 \mu M (1.2) for EMD60480, 17 \mu M (1.1) for cromakalim, and 855 \mu M (0.9) for diazoxide. Similar values were obtained in a separate preparation. The K\textsubscript{50} values for the benzopyran derivatives are reasonably similar to those observed for mitoK\textsubscript{ATP}; however, the K\textsubscript{50} value for diazoxide is about 2000-fold higher. In contradistinction to the finding with mitoK\textsubscript{ATP}, the Hill slopes for activation of cellK\textsubscript{ATP} were indistinguishable from 1 for all of the KCOs tested.

Activation of ATP-Sensitive K\textsuperscript{+} Flux in Intact Mitochondria by K\textsuperscript{+} Channel Openers—The preceding results appear to conflict with previous work (6, 7) showing very low potencies for KCO activation of K\textsuperscript{+} flux in mitochondria. Accordingly, it was important to determine whether the high potencies observed in Fig. 1 are also observed in situ.

Fig. 3 contains representative light-scattering traces from rat liver mitochondria respiring on ascorbate-TMPD. Swelling in K\textsuperscript{+} salts (tracea) was sharply inhibited by addition of 100 \mu M
ATP (down arrow to trace b) to levels close to those observed in TEA$^-$ salts (trace c). In agreement with previous results (10), higher [ATP] had no further effect in K$^+$ medium, and ATP had no effect on TEA$^-$ flux (not shown). When 20 μM cromakalim was included in the assay medium containing 100 μM ATP, ATP inhibition was prevented (up arrow to trace d, Fig. 3). In the absence of ATP, cromakalim had no effect on the control rate up to 100 μM, the highest dose tested. When cromakalim was added during the inhibited state, ATP inhibition was reversed (not shown).

Fig. 4 contains dose-response curves for activation of K$^+$ flux by diazoxide, cromakalim, and EMD60480 in mitochondria. Activation was measured relative to rates in the presence of 100 μM ATP and 1 mM Mg$^{2+}$, conditions in which the K$\text{ATP}_c$ for ATP inhibition is 2-3 μM (13). The estimated K$\text{ATP}_c$ values were 2.3 μM for diazoxide, 6.3 μM for cromakalim, and 5.4 nM for EMD60480.

As in proteoliposomes, these drugs stimulated K$^+$ flux only when K$^+$ flux was inhibited by Mg$^{2+}$ and ATP. In doses 20-fold higher than their respective K$\text{ATP}_c$ values, these KCOs had no effect on flux through the uninhibited channel. This effect was verified in media containing Mg$^{2+}$ alone, ATP alone, and lacking both Mg$^{2+}$ and ATP.

**DISCUSSION**

This is the first report showing that KCOs activate mitoK$\text{ATP}_c$ over the same dose range as they activate cellK$\text{ATP}_c$. This finding was observed in mitochondria and in proteoliposomes reconstituted with mitoK$\text{ATP}_c$ and raises the possibility that mitoK$\text{ATP}_c$ may be activated by KCOs in vivo. Kinetic parameters differed between intact mitochondria and the reconstituted preparations. As previously reported (13), the K$\text{ATP}_c$ for ATP inhibition is lower in mitochondria (2–3 μM) than in proteoliposomes (20–25 μM). We now show that the K$\text{ATP}_c$ values for diazoxide and cromakalim are about 6-fold higher in mitochondria than in liposomes. On the other hand, the K$\text{ATP}_c$ for EMD60480 is about the same in the two preparations. These differences may reflect regulatory complexity in intact mitochondria, which is lost upon extraction and reconstitution.

In the dose ranges studied, KCOs had no effect on K$^+$ flux when Mg$^{2+}$ and/or ATP were omitted from the assay medium. The lack of effect of KCOs on the open channel is also characteristic of cellK$\text{ATP}_c$ (20). The finding that KCOs in low doses have no effect on the uninhibited channel is also consistent with the results of Belyaeva et al. (6) and Szewczyk et al. (7), who did not include Mg$^{2+}$ and ATP in the assay medium used for their studies.

**Physical Consequences of Opening and Closing MitoK$\text{ATP}_c$ — Opening of mitoK$\text{ATP}_c$ will shift the balance between K$^+$ uniport and K$^+$/H$^+$ antiport, causing transient net K$^+$ uptake and matrix swelling to a higher steady-state volume (21). Halestrap (22) has established that increasing matrix volume over a fairly narrow range greatly activates electron transport at the point where electrons feed into ubiquinone, and he has suggested (23) that this sequence may be triggered by opening of mitoK$\text{ATP}_c$. Thus, opening of mitoK$\text{ATP}_c$ may be a necessary component of the cellular signals calling, for example, for higher ATP production to support increased work in heart or for faster β oxidation of fatty acids to support thermogenesis in brown adipose tissue. Conversely, blocking mitoK$\text{ATP}_c$ may interfere with the cell’s response to these signals.

MitoK$\text{ATP}_c$ as a Pharmacological Receptor—Recognition of mitoK$\text{ATP}_c$ as an intracellular receptor for KCOs adds a new dimension to the KCO pharmacology, which has heretofore focused exclusively on plasma membrane K$\text{ATP}_c$ channels. Pharmacological regulation of K$\text{ATP}_c$ channels has many important, tissue-dependent consequences (1–3); however, the receptors for these effects have not yet been identified, and a mitochondrial contribution cannot be excluded. The role of K$\text{ATP}_c$ channels in pancreatic β cells is a case in point. Flatt et al. (24) have recently shown that Ca$^{2+}$-dependent insulin release from electropерmeabilized β cells is stimulated by glyburide and inhibited by diazoxide. Because plasma membrane K$\text{ATP}_c$ channels are inoperative in the permeabilized cell, these effects point to an intracellular receptor for these agents (24).

A particularly exciting development in heart is the finding by Grover and colleagues (5, 25) and others (26, 27) that KCOs are cardioprotective during experimental ischemia. KCO-treated hearts maintained higher ATP levels and exhibited reduced infarct size and enhanced post-ischemic recovery upon reperfusion. All of these effects were blocked by glyburide, which is contraindicated in patients susceptible to cardiac ischemia. Preconditioning, in which a period of brief ischemia reperfusion
protects the heart against subsequent ischemic damage (28), was also blocked by glyburide (29). These pharmacological effects point to a role of K$_{ATP}$ channels in myocardial protection; but, again, the receptor for these effects has not been identified, and a mitochondrial site of action cannot be excluded (25).

Exploration of this possibility is aided by the existence of receptor subtypes among K$_{ATP}$ channels (1). For example, cromakalim is a potent activator of cellK$_{ATP}$ from heart and vascular smooth muscle (29) but has a minimal effect on insulin secretion (4, 30). Diazoxide is a potent vasodilator (4) and also reduces insulin secretion (31) but has little effect on cardiac cellK$_{ATP}$ (18). This raises the question whether mitoK$_{ATP}$ and cellK$_{ATP}$ from the same cell differ pharmacologically. Accordingly, we have compared drug sensitivities of cardiac mitoK$_{ATP}$ and cellK$_{ATP}$ reconstituted from beef heart. These experiments yielded the following preliminary results: (i) mitoK$_{ATP}$ from heart and liver do not differ significantly in their drug sensitivities (K$_{1/2}$ values); (ii) cardiac mitoK$_{ATP}$ and cardiac cellK$_{ATP}$ exhibit similar sensitivities to benzopyran derivatives; however, (iii) cardiac mitoK$_{ATP}$ is about 2000 times more sensitive to diazoxide than cardiac cellK$_{ATP}$. The low sensitivity of reconstituted cardiac cellK$_{ATP}$ to diazoxide is entirely consistent with previous reports (18). The inferred existence of receptor subtypes within the cardiac myocyte may provide a means to determine the site of cardioprotective action of K$^+$ channel openers.

Acknowledgments—The authors thank Craig Semrad and Jarmina Pauckova for their excellent assistance and Dr. Norbert Beier of E. Merck, Darmstadt, who provided the benzopyranyl derivatives.

REFERENCES
1. Cook, N. S., and Quast, U. (1990) in Potassium Channels (Cook, N. S., ed), pp. 181-231, Ellis Horwood Ltd., Chichester, UK
2. Escande, D., and Henry, H. (1993) Eur. Heart J. 14, 2-9
3. McPherson, G. A. (1993) Gen. Pharmacol. 24, 275-281
4. Quast, U., and Cook, N. S. (1989) J. Pharmacol. Exp. Ther. 250, 261-270
5. Grover, G. J., McCullough, J. R., Slipher, P. G., Conder, M. L., and Henry, D. (1989) J. Pharmacol. Exp. Ther. 251, 96-104
6. Belyaeva, E. A., Szewczyk, A., Mikolajek, B., Nalecz, M. J., and Woltczak, L. (1993) Biochem. Mol. Biol. Int. 31, 493-500
7. Szewczyk, A., Wójcik, G., and Nalecz, M. J. (1995) Biochem. Biophys. Res. Commun. 207, 126-132
8. Paucek, P., Mironova, G., Mahdi, F., Beavis, A. D., Woldegiorgis, G., and Garlid, K. D. (1992) J. Biol. Chem. 267, 26062-26069
9. Garlid, K. D., Sun, X., Paucek, P., and Woldegiorgis, G. (1995) Methods Enzymol. 260, 331-348
10. Periyasamy, S. M., Kakar, S. S., Garlid, K. D., and Askari, A. (1990) J. Biol. Chem. 265, 6035-6041
11. Jones, L. R., and Besch, H. R., Jr. (1984) Methods Pharmacol. 5, 1-12
12. Paucek, P., and Garlid, K. D. (1993) Biophys. J. 64, A311
13. Beavis, A. D., Lu, Y., and Garlid, K. D. (1993) J. Biol. Chem. 268, 997-1004
14. Beavis, A. D., Brannan, R. D., and Garlid, K. D. (1985) J. Biol. Chem. 260, 13424-13432
15. Garlid, K. D., and Beavis, A. D. (1985) J. Biol. Chem. 260, 13434-13441
16. Guy, H. R., and Durell, S. R. (1994) Soc. Gen. Physiol. Ser. 49, 197-212
17. Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., IV, Boyd, A. E., III, Gonzalez, G., Herrera-Sosa, H., Nguy, K., Bryan, J., and Nelson, D. A. (1995) Science 268, 423-425
18. Faire, J. F., and Findlay, I. (1989) Biochim. Biophys. Acta 984, 1-5
19. Paucek, P., Schindler, P. A., Yarov-Yarovoy, V., and Garlid, K. D. (1996) Biophys. J. 70, A1688
20. Thuringer, D., and Escande, D. (1989) Mol. Pharmacol. 36, 897-902
21. Garlid, K. D. (1988) in Integration of Mitochondrial Function (Lemasters, J. J., Hackenbrock, C. R., Thurman, R. G., and Westerhoff, H. V., eds) pp. 257-276, Plenum Publishing, New York
22. Halestrap, A. P. (1989) Biochim. Biophys. Acta 973, 355-382
23. Halestrap, A. P. (1994) Biochem. Soc. Trans. 22, 522-529
24. Piatt, P. R., Shibler, O., Szewczyk, J., and Berggren, P.-O. (1994) Diabetes Metab. 20, 157-162
25. Grover, G. J. (1994) J. Cardiovasc. Pharmacol. 24, S18-S27
26. Cole, W. C. (1993) Cardiovasc. Drugs Ther. 1993, 527-537
27. Gross, G. J., and Auchampach, J. A. (1992) Cardiovasc. Res. 26, 1011-1016
28. Murry, C. E., Jennings, R. B., and Reimer, K. A. (1986) Circulation 74, 1124-1136
29. Escande, D., Thuringer, D., Leguerno, S., and Cavero, I. (1988) Biochem. Biophys. Res. Commun. 154, 620-625
30. Lazdunski, M. (1994) J. Cardiovasc. Pharmacol. 24, 51-55
31. Trube, G., Rorsman, P., and Ohno-Shosaku, T. (1986) Pfluegers Arch. 407, 493-499
32. Paucek, P., Yarov-Yarovoy, V., Sun, X., and Garlid, K. D. (1995) Biophys. J. 68, A145